A Phase 4 interventional study of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Hoffmann-La Roche. Completed at 38 sites in 8 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-06-13.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.
Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 6th largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 4, and was the 5th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:
First Affiliated Hospital of Wenzhou Medical University
Ages 40+
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2016.
This study's enrollment of 89 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 49 across the 16 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, this one is the 17th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2016, is the only one in phase 4, and was the 18th registered.
Hoffmann-La Roche’s Idiopathic Pulmonary Fibrosis studies by the year they started, since 2000.
1 of the studies testing nintedanib in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07583589First Affiliated Hospital of Wenzhou Medical UniversityNintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 29 in Idiopathic Pulmonary Fibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical study will evaluate the safety and tolerability of combination treatment of nintedanib and pirfenidone in participants with IPF. Eligible participants must have received pirfenidone for at least 16 weeks on a stable dose. Nintedanib will be added on Day 1 of the study as a combination treatment for IPF for 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
Drug: Nintedanib · Drug: Pirfenidone
Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.
Also known as: Ofev
Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
Also known as: Esbriet
Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day
Time frame: Week 24
Percentage of Participants With Adverse Events and Serious Adverse Events
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Baseline up to Week 28
Percentage of Participants Who Discontinue Pirfenidone, Nintedanib, or Both Study Treatments Because of Adverse Events Before the Week 24 Visit
Time frame: Baseline up to Week 24
Total Number of Participant Days of Combination Treatment With Pirfenidone and Nintedanib
Time frame: Baseline up to Week 24
Total Number of Days From the Initiation of Combination Treatment to Discontinuation of Pirfenidone, Nintedanib, or Both Study Treatments
Time frame: Baseline up to Week 24
Participants with idiopathic pulmonary fibrosis were recruited for this study.
| Milestone | Pirfenidone+Nintedanib |
|---|---|
| Started | 89 |
| Completed | 73 |
| Not completed | 16 |
| Withdrew: Adverse event | 13 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Listed in active lung transplant list | 1 |
| Withdrew: Does not want to take nintedanib | 1 |
| Percentage of Participants | Pirfenidone+Nintedanib |
|---|---|
| Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day | 77.5 (67.4 to 85.7) |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| Percentage of Participants | Pirfenidone+Nintedanib |
|---|---|
| Adverse Event | 98.9 |
| Serious Adverse Event | 18.0 |
| Percentage of Praticipants | Pirfenidone+Nintedanib |
|---|---|
| Percentage of Participants Who Discontinue Pirfenidone, Nintedanib, or Both Study Treatments Because of Adverse Events Before the Week 24 Visit | 14.6 (8.0 to 23.7) |
| Participant Days | Pirfenidone+Nintedanib |
|---|---|
| Total Number of Participant Days of Combination Treatment With Pirfenidone and Nintedanib | 13330 |
| Number of Days | Pirfenidone+Nintedanib |
|---|---|
| Total Number of Days From the Initiation of Combination Treatment to Discontinuation of Pirfenidone, Nintedanib, or Both Study Treatments | 149.8 ± 43.93 |
Collected over Baseline up to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pirfenidone+Nintedanib | 0/89 (0%) | 16/89 (18%) | 83/89 (93.3%) |
| Event | Pirfenidone+Nintedanib |
|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 3/89 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 2/89 |
| PneumomediastinumRespiratory, thoracic and mediastinal disorders | 1/89 |
| Cholecystitis infectiveInfections and infestations | 1/89 |
| InfluenzaInfections and infestations | 1/89 |
| PneumoniaInfections and infestations | 1/89 |
| TracheobronchitisInfections and infestations | 1/89 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/89 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/89 |
| PancreatitisGastrointestinal disorders | 1/89 |
| Event | Pirfenidone+Nintedanib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 52/89 |
| NauseaGastrointestinal disorders | 44/89 |
| VomitingGastrointestinal disorders | 29/89 |
| CoughRespiratory, thoracic and mediastinal disorders | 20/89 |
| FatigueGeneral disorders | 14/89 |
| Decreased appetiteMetabolism and nutrition disorders | 14/89 |
| HeadacheNervous system disorders | 13/89 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 10/89 |
| DizzinessNervous system disorders | 9/89 |
| Viral upper respiratory tract infectionInfections and infestations | 9/89 |
Safety population included all participants who had received at least one dose of investigational medicinal product on or after Day 1.
| Age, Continuous(Years) | Pirfenidone+Nintedanib |
|---|---|
| Mean | 68.2 ± 6.82 |
| Sex: Female, Male(Participants) | Pirfenidone+Nintedanib |
|---|---|
| Female | 18 |
| Male | 71 |
| Ethnicity (NIH/OMB)(Participants) | Pirfenidone+Nintedanib |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 74 |
| Unknown or Not Reported | 6 |
| Race/Ethnicity, Customized(Participants) | Pirfenidone+Nintedanib |
|---|---|
| White | 84 |
| Black or African American | 3 |
| Asian | 1 |
| Asian/White | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2016 to primary completion in May 2017, 16 months.
Results were first posted in Jun 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nintedanib · Pirfenidone
Idiopathic Pulmonary Fibrosis →